Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to -$2.1 million.

  • Pharma's Free Cash Flow fell 10673.17% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year decrease of 1227.3%. This contributed to the annual value of -$4.9 million for FY2025, which is 805.7% up from last year.
  • As of Q3 2025, Pharma's Free Cash Flow stood at -$2.1 million, which was down 10673.17% from -$1.4 million recorded in Q2 2025.
  • Over the past 5 years, Pharma's Free Cash Flow peaked at -$541000.0 during Q1 2024, and registered a low of -$2.6 million during Q1 2021.
  • In the last 5 years, Pharma's Free Cash Flow had a median value of -$1.7 million in 2023 and averaged -$1.7 million.
  • In the last 5 years, Pharma's Free Cash Flow skyrocketed by 6445.47% in 2024 and then tumbled by 10673.17% in 2025.
  • Quarter analysis of 5 years shows Pharma's Free Cash Flow stood at -$2.4 million in 2021, then increased by 8.94% to -$2.2 million in 2022, then rose by 25.78% to -$1.7 million in 2023, then grew by 18.79% to -$1.3 million in 2024, then plummeted by 57.66% to -$2.1 million in 2025.
  • Its Free Cash Flow stands at -$2.1 million for Q3 2025, versus -$1.4 million for Q2 2025 and -$748000.0 for Q1 2025.